Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma

[1]  M. Omran,et al.  A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. , 2020, Annals of hepatology.

[2]  R. Lencioni,et al.  mRECIST for HCC: Performance and novel refinements. , 2020, Journal of hepatology.

[3]  I. Endo,et al.  Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification , 2019, Annals of Surgical Oncology.

[4]  R. Anwar,et al.  Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian Patients , 2018, Asian Pacific journal of cancer prevention : APJCP.

[5]  T. Chiu,et al.  Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma , 2018, BMC Cancer.

[6]  S. Kim,et al.  Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas , 2017, Scientific Reports.

[7]  S. Puig,et al.  Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine , 2017, Nature.

[8]  L. Roberts,et al.  Should AFP (or Any Biomarkers) Be Used for HCC Surveillance? , 2017, Current Hepatology Reports.

[9]  Lei Chen,et al.  Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells , 2017, Oncotarget.

[10]  T. Nakano,et al.  Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells , 2017, Oncogene.

[11]  Hossam A. Hodeib,et al.  Serum Midkine and Osteopontin Levels as Diagnostic Biomarkers of Hepatocellular Carcinoma , 2017, Electronic physician.

[12]  M. Wirth,et al.  Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer , 2016, Oncology letters.

[13]  T. Iseli,et al.  Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma , 2016, PloS one.

[14]  A. Shiotani,et al.  Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma , 2016, Cancer medicine.

[15]  W. Kim,et al.  Clinical significance of midkine expression in sporadic desmoid tumors , 2016, Oncology letters.

[16]  Huilian Huang,et al.  Role of midkine-progranulin interaction during angiogenesis of hepatocellular carcinoma. , 2015, International journal of clinical and experimental pathology.

[17]  B. Lang,et al.  Co-expression of midkine and pleiotrophin predicts poor survival in human glioma , 2014, Journal of Clinical Neuroscience.

[18]  K. Rau,et al.  Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma , 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[19]  X. Wang,et al.  Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[20]  J. Marrero,et al.  Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. , 2005, Journal of hepatology.

[21]  Matthew S. Johnson,et al.  The diagnosis and treatment of hepatocellular carcinoma. , 1998, Seminars in diagnostic pathology.

[22]  K. Kamiya,et al.  Midkine Promotes Atherosclerotic Plaque Formation Through Its Pro-Inflammatory, Angiogenic and Anti-Apoptotic Functions in Apolipoprotein E-Knockout Mice. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[23]  G. Gores,et al.  Hepatocellular carcinoma , 2016, Nature Reviews Disease Primers.